// App-Quantinova.ai

11043 : Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation.

Researchers

Presenter

  • Diana Miao

Principal Investigators

  • Dennis Adeegbe

  • Scott J. Rodig

  • Sachet Shukla

  • Ali Amin-Mansour

  • Scott L. Carter

  • Catherine Wu

  • Kwok-Kin Wong

  • Chandrajit P. Raut

  • Patrick Alexander Ott

  • Eliezer Mendel Van Allen

  • George D. Demetri

  • Suzanne George

Medical Centers

  • Broad Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Pathology, Division of Hematopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

  • Broad Institute, Cambridge, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Center/Brigham and Women's Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Leiomyosarcoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved